Pazopanib therapy for desmoid tumors in adolescent and young adult patients
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2018 · 1 min read
In brief
In brief
This retrospective study evaluates pazopanib as a targeted therapy for desmoid tumors in adolescent and young adult patients who failed conventional treatments. Pazopanib demonstrated superior response rates compared to established therapies including surgery, vinblastine/methotrexate, and sulindac/tamoxifen, with partial responses in multiple cases and dramatic volumetric tumor reduction.
Written by the GCMD Library team from the article.
Statements in this article
Surgical resection of desmoid tumors had a 68% recurrence rate in this cohort.
Of eight patients who received vinblastine/methotrexate, only one had a partial response by RECIST 1.1 and five had stable disease.
62.5% of patients treated with vinblastine/methotrexate required additional therapy.
Of seven patients who received sulindac/tamoxifen, none showed objective improvement.
Pazopanib demonstrated best responses by RECIST of partial response in two of seven and stable disease in six of seven tumors.
A partial response of 66% was observed with pazopanib in a patient who had failed multiple prior therapies.
Mesenteric desmoid tumor showed partial response to pazopanib.
Maximum volumetric decrease by T2-weighted MRI with pazopanib therapy was 97%.